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Background: Atrial fibrillation (AF) and heart failure (HF) are both common comorbid conditions of elderly patients
with acute coronary syndrome (ACS), but published data on their associated clinical and economic outcomes are
limited.
Methods: Our study included patients from the Medicare Current Beneficiary Survey with an incident
hospitalization for ACS between 03/01/2002 and 12/31/2006. Applying population weights, we identified 795
incident ACS patients, representing more than 2.5 million Medicare beneficiaries. Of this population, 13.1% had
comorbid AF, and 22.9% had HF, which were identified from Medicare claims during the 6 months prior to the
first ACS event (index date) Subsequent cardiovascular (CV) hospitalizations and mortality were compared using
Kaplan–Meier curves. Cox proportional hazards regressions were used to estimate the relative risk of AF and HF on
CV events and mortality. Healthcare costs were summarized for the calendar year in which the incident ACS event
occurred.
Results: HF was associated with a 41% higher risk of mortality (HR = 1.41; 95% confidence interval [CI] 1.05–1.89).
Both AF (HR = 1.46; 95% CI 1.14–1.87) and HF (HR = 1.61; 95% CI 1.26–2.06) were associated with higher risks of
subsequent CV events. During the year of the incident ACS event, ACS patients with comorbid AF or HF had
approximately $18,000 higher total healthcare costs than those without these comorbidities.
Conclusion: Using a nationally representative sample of Medicare beneficiaries, we observed a significantly higher
clinical and economic burden of patients hospitalized for ACS with comorbid AF and HF compared with those
without these conditions.
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Acute coronary syndrome (ACS) is one of the most
common cardiovascular illnesses in the United States; in
2009, close to 1.2 million hospital discharges in the
United States had an ACS diagnosis [1]. ACS results in
significant morbidity and mortality [2]. Atrial fibrillation
(AF), the most common sustained cardiac arrhythmia,
and heart failure (HF) are frequent complications of
ACS [3-5]. AF and HF share many antecedent risk fac-
tors, and approximately 40% of individuals with either of
these conditions will develop the other [5]. Moreover,* Correspondence: Shih-Yin.Chen@evidera.com
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reproduction in any medium, provided the orthe development of AF appears to increase the risk of
mortality from HF and vice versa [3-5].
AF prevalence increases with age. The prevalence of
AF in the United States, estimated to be between 2.7
and 6.1 million in 2010, is expected to rise to between
5.6 and 12 million in 2050, as the population ages [6-8].
The incremental total healthcare cost of patients with
AF, when compared with those without AF, was esti-
mated to be $26 billion in 2008 US dollars, of which $6
billion was associated with services related to the AF
diagnosis [9].
According to the American Heart Association, the
prevalence of HF is also increasing, from 2.8% in 2010
to a projected 3.5% in 2030, when an additional 3td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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215% increase in projected direct medical costs (from
$24.7 billion–$77.7 billion) and an 80% increase in pro-
jected indirect costs (from $9.7 billion–$17.4 billion)
related to HF between 2010 and 2030 [10].
Past studies have examined the impact of comorbid
AF and HF on the mortality of patients with ACS in the
real world. In a few recent studies, the occurrence of AF
among hospitalized ACS patients ranged from 4.4% to
11.8%, and was associated with mortality up to 1 year
post-discharge [11-13]. The Global Registry of Acute Cor-
onary Events (GRACE), one of the largest multinational
registries for ACS, also reported the impact of HF, when
developed as a complication during hospitalization, in
patients with ACS [14]. Although these studies have dem-
onstrated the adverse effects of comorbid AF and HF in
ACS patients in the hospital and up to 12 months post-
discharge, the associated impact on outcomes beyond 1
year has not been elucidated. Eventually, these patients
transition from acute care back to the community and are
managed with medical therapies. Further evaluation of
long-term clinical outcomes is needed, in order to address
knowledge gaps and understand the true burden of
disease. Moreover, there are limited published data on
economic outcomes, such as readmission, which are im-
portant from the payer’s perspective, especially Medicare,
because close to half of ACS patients are older than 65
years of age [15].
The objective of this study was to evaluate outcomes
in patients with ACS and comorbid AF and HF in




We analyzed data between 2001 and 2006 from the
Medicare Current Beneficiary Survey (MCBS), a panel
survey sponsored by the Centers for Medicare and
Medicaid Services. MCBS uses a multistage, stratified
sampling design to allow findings to be representative of
all Medicare beneficiaries [16]. A panel of approximately
4000 beneficiaries is recruited each year and followed for
4 years, yielding data from four panels of approximately
16,000 beneficiaries in a given year for cross-sectional
analysis.
MCBS collects a wide variety of data on socioeconomic
characteristics and healthcare resource utilization and
costs. Survey responses regarding healthcare use are com-
bined with Medicare Part A and Part B administrative
billing claims to provide a complete picture of beneficiar-
ies’ use of health services. For each panel, 3 years of
complete healthcare utilization data are collected, includ-
ing, Medicare- and non-Medicare–reimbursed healthcare
utilization. The medical claims reimbursed by Medicarecontain information on dates of service; International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM) diagnosis and procedure codes; and
costs. Data analyzed were encrypted and compliant with
the Health Insurance Portability and Accountability Act;
therefore, the study was exempted from institutional re-
view board review.
Study sample selection
ACS patients were selected from the MCBS based on in-
patient medical claims with an associated diagnosis of
ACS (ICD-9-CM: 410.×× [except 410.×2], 411.1×, and
411.8×) in any diagnosis fields from the Medicare Part A
claims between March 1, 2002, and December 31, 2006.
We chose this period after the approval of clopidogrel,
which became the standard of care, to reflect the current
burden with all available evidence-based medical therap-
ies. The date of the first ACS admission was denoted as
the index date. Beneficiaries had to have been in the
database for at least 6 months prior to the index date to
be included, but those who had any ACS events during
those 6 months were excluded. Patients were then
stratified into cohorts based on whether they had any
Medicare claims with ICD-9-CM diagnosis codes for AF
(427.31) or HF (428.xx) during the 6 months prior to the
index date.
Patient characteristics
Baseline demographic and socioeconomic characteris-
tics, including age, gender, race, region of residence, em-
ployment status, education status, income level, marital
status, and living arrangements were examined. Medi-
care claims during the 6 months prior to the index date
were used to identify hypertension and hyperlipidemia
and to measure the Charlson Comorbidity Index (CCI),
a score derived by weighting 17 conditions to predict
mortality [17].
Healthcare costs
MCBS combines survey responses and Medicare claims to
report total healthcare costs, including both Medicare-
and non-Medicare–reimbursed services. Annual health-
care costs were summarized for the calendar year in which
the incident ACS event occurred. We reported combined
costs of plan-paid and beneficiary out-of-pocket payments.
Total healthcare costs and costs by settings, including
inpatient hospital, medical provider, short-term facility,
long-term facility, outpatient hospital, prescribed medi-
cine, home health, dental, and hospice were reported.
Study outcomes
Mortality was ascertained from hospital discharge status
(actual date available) or from the survey data (reported
monthly). Cardiovascular (CV)-related rehospitalizations
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associated diagnoses (Table 1). All outcomes were evalu-
ated from the index date until loss of follow-up (up to
2.5 years).
Analysis
Descriptive results were reported by comparing AF vs
non-AF and HF vs non-HF beneficiaries. Means and
standard errors were reported for continuous variables
and proportions for categorical variables. Chi-squared
tests were used to detect differences for categorical vari-
ables between cohorts, and Student’s t-test was used for
mean age. Since healthcare costs were skewed, we used
an unadjusted generalized linear regression model with
log link and gamma distribution to test for statistical dif-
ferences [18]. Kaplan–Meier curves were plotted for sur-
vival probability and outcome-free survival probability
for CV-related readmission, censoring at loss of follow-
up. The log-rank test was used to detect unadjusted dif-
ferences in Kaplan–Meier curves between study cohorts.
Cox proportional hazards regressions were used to as-
sess the risk of mortality and CV-related readmission as-
sociated with comorbid AF or HF, adjusting for patients’
age, gender, race, income level, education level, marital
status, and a CCI modified by the exclusion of AF and
HF. Hazard ratios (HR) and 95% confidence intervals
(CI) were reported. A generalized linear regression
model with log link and gamma distribution was also
run on total healthcare costs adjusted for the similar
covariates to assess the economic burden associated
×with AF and HF. Analyses were conducted using sur-
vey command from SAS 9.2 (Cary, NC) and STATA 11.0
(College Station, TX) incorporating population weights
and clustering from multistage sampling design for
robust estimates of variances.
Results
Over a 58-month period—between March 2002 and
December 2006—this study identified 795 patients with
ACS, representing close to 2.5 million beneficiaries.
Of these patients, 13.1% had AF, and 22.9% had HF
(Table 2). There were cross-cohort differences in patient
characteristics when comparing HF with non-HF bene-Table 1 Diagnosis codes to identify cardiovascular-related
rehospitalization
ICD-9-CM codes Description
410.×-414.× Ischemic heart disease
420.×-429.× Other forms of heart disease
430.×-438.× Cerebrovascular disease
402.9× Unspecified hypertensive heart disease
785.0 Tachycardia unspecified
785.1 Palpitationsficiaries. Compared with patients without HF, those with
HF were older (78.5 years vs 75.4 years, P = 0.001), more
likely to be institutionalized (14% vs 4%, P < 0.001) or to
have hypertension (78% vs 65%, P < 0.001), and less likely
to be currently employed (1.6% vs 9.9%, P < 0.001). Most
other characteristics were similar between the AF and
non-AF cohorts. Both AF and HF patients had a signifi-
cantly higher CCI scores than ACS patients without
these conditions.
The ACS patients with AF had significantly higher
annual total healthcare costs than those without AF,
with mean costs of $66,586 and $48,031, respectively
(P < 0.001) (Table 3). Inpatient hospital ($35,737 vs
$26,385; P = 0.003) and medical provider costs ($12,284
vs $8,866; P < 0.001) were the major cost drivers and
were significantly higher for patients with AF compared
with those without it. Similar results were found in the
HF cohort comparisons. Compared with non-HF benefi-
ciaries, those with HF had higher total costs ($64,548 vs
$46,268; P < 0.001), with inpatient hospital ($32,782 vs
26,070; P = 0.013), and medical provider costs ($10,605
vs $8,929; P = 0.024) being the two major components.
Figure 1 shows that both AF and HF patients had
significantly lower probabilities of survival compared
with those without these conditions (P < 0.001 for both).
When assessing CV-related readmissions among ACS
patients who were discharged alive (Figure 2), AF and
HF patients also had significantly lower probabilities of
outcome-free survival than their counterparts without
these conditions (P < 0.001 for both). After adjusting
for patient characteristics (Table 4), HF was associated
with a 41% higher risk of mortality (HR = 1.41; 95% CI
1.05–1.89), whereas increases in mortality risk associated
with AF were not significant (HR = 1.15; 95% CI 0.81–
1.64). Other factors associated with a higher risk of
mortality included older age (<75 years as reference;
75–84 years HR = 2.68, 95% CI 1.72–4.19; 85+ years
HR = 4.98, 95% CI 3.04–8.14) and a CCI ≥4 (HR = 2.19;
95% CI 1.61–2.99 compared with CCI = 0–1). Both AF
(HR = 1.46; 95% CI 1.14–1.87) and HF (HR = 1.61;
95% CI 1.26–2.06) were associated with higher risks
of CV-related readmissions. No other variables in the
model of CV-related readmissions were significant.
After adjusting for patient socio-demographic char-
acteristics (Table 5), we found ACS patients with AF
incurred healthcare costs that were 1.21 times of the
costs in patients without AF (P = 0.008). ACS patients
with HF incurred healthcare costs that were 1.25
times of the costs in patients without HF (P = 0.001).
Patients with CCI score equal to or greater than 4
also had higher total healthcare costs compared to
those with CCI = 0 or 1 (P = 0.004). Other socio-
demographic variables in the model were not statisti-
cally significant.
Table 2 Demographic and socioeconomic characteristics of Acs patients by comorbid arial fibrillation and heart failure
AF cohorts HF cohorts
AF Non-AF P value HF Non-HF P value
Number of patients 106 689 198 597
Represented number of patients (%) 332553 (13.1%) 2209658 (86.9%) 582767 (22.9%) 1959444 (77.1%)
Age: mean (SE) 77.87 (0.95) 75.79 (0.38) 0.071 78.48 (0.70) 75.35 (0.41) 0.001
Male (%) 45.20 49.76 0.392 42.16 51.24 0.171
Race (%): N/A N/A
White 85.91 86.08 82.65 87.08
Non-white 14.09 13.76 16.77 12.92
Missing or unknown 0.00 0.15 0.58 0.00
Region (%): N/A 0.215
Northeast 20.36 17.68 20.45 17.32
Midwest 33.22 23.34 20.39 25.90
South 36.74 43.11 40.04 42.95
West 9.68 13.47 16.01 12.08
Puerto Rico 0.00 2.39 3.11 1.77
Education level (%): 0.477 0.001
Less than high school 41.29 35.53 46.00 33.39
High school or more 57.53 63.17 51.48 65.68
Unknown/Missing 1.18 1.31 2.52 0.92
Marital status (%): N/A N/A
Married 32.36 46.31 32.68 48.00
Widowed 48.18 37.53 51.69 35.13
Other (separated/divorced/never married) 19.46 16.15 15.63 16.87
Missing 0.00 0.10 0.00 0.11
Living situation (%): 0.480 <0.001
Community dwelled 92.02 93.89 86.00 95.92
Institutionalized 7.98 6.11 14.00 4.08
Employment status: currently employed (%) 2.97 8.80 0.077 1.61 9.94 <0.001
Income level: less than $25,000 (%) 71.66 66.56 0.268 78.15 63.98 <0.001
Charlson Comorbidity Index: Mean (SE) 3.82 (0.27) 2.23 (0.09) <0.05 4.45 (0.20) 1.84 (0.08) <0.05
Distribution of Charlson Comorbidity score (%): <0.001 <0.001
0–1 14.89 43.85 10.74 48.78
2 16.84 20.69 10.95 22.93
3 23.29 13.24 24.13 11.70
4+ 44.97 22.23 54.19 16.58
Hypertension (%) 75.05 66.84 0.071 77.93 64.93 <0.001
Hyperlipidemia (%) 46.48 47.58 0.842 47.93 47.29 0.877
AF, atrial fibrillation; HF, heart failure; N/A, not applicable (statistics could not be produced when any cell size was equal to zero); SE, standard error.
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In this nationally representative sample of Medicare
beneficiaries, ACS with comorbid AF and HF was asso-
ciated with greater clinical and economic burdens,
compared with ACS without these conditions. The
prevalence rate of AF reported in this study (13.1%) is
slightly higher than in a previous study that reportedprevalence rates of preexisting AF (11.4%) before hospi-
talization for ACS, likely because we studied an older
population [11]. Similarly, the prevalence rate of preex-
isting HF was also higher (22.9%) than in two earlier
studies, probably reflecting age differences in the study
populations. However, the prevalence might not be dir-
ectly comparable, as those prior studies reported HF on
Table 3 Annual healthcare costs of ACS patients by comorbid arial fibrillation and heart failure
AF cohorts HF cohorts
AF Non-AF P value HF Non-HF P value
Annual total healthcare costs: mean (SE) $66586 (4309) $48031 (1500) <0.001 $64548 (3878) $46268 (1355) <0.001
Inpatient hospital $35737 (2989) $26385 (1108) 0.003 $32782 (2667) $26070 (1005) 0.013
Medical provider $12284 (834) $8866 (414) <0.001 $10605 (673) $8929 (432) 0.024
Short-term facility $5159 (1316) $2891 (294) 0.036 $5111 (903) $2615 (344) 0.005
Long-term facility $3335 (885) $3100 (380) 0.823 $7018 (987) $1974 (296) <0.001
Outpatient hospital $5169 (1170) $2666 (258) 0.009 $3950 (747) $2709 (256) 0.077
Prescribed medicine $2704 (343) $2531 (95) 0.623 $2556 (288) $2553 (99) 0.993
Home health $2005 (357) $1165 (132) 0.011 $2061 (300) $1041 (125) <0.001
Dental $92 (34) $225 (30) 0.029 $66 (16) $250 (34) <0.001
Hospice $100 (58) $202 (57) 0.287 $398 (155) $126 (47) 0.042
AF, atrial fibrillation; HF, heart failure; SE, standard error.
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patients with prior HF (prevalence rates 22.7% and 13%,
respectively) [14,19]. With up to 2.5 years of follow-up,
the unadjusted results in our study showed that patients
with comorbid AF or HF were at a higher risk of mortal-
ity and CV-related readmission than their counterparts
without AF or HF. The adjusted results, controlling for
patient characteristics, showed a 46% increased risk of
CV-related readmission associated with AF and a 61%
risk of CV-related readmission and 41% increased risk of
mortality associated with HF.
The major distinctions between our study and earlier
studies examining the risk of morbidity and mortality as-
sociated with AF in an ACS population are that 1) our
study sample included Medicare beneficiaries who were
aged 65 years or older, and 2) we captured preexisting
AF. Unlike prior observational studies with access to
medical charts to determine onset of AF during hospita-
lization [11-13], our use of medical claims as a source of
diagnosis precluded the identification of new-onset AF.
Lopes et al and Torres et al demonstrated that AF com-
plicating ACS was associated with a relative risk of 2.89

























Figure 1 Kaplan–Meier curves for survival from admission of acute co
heart failure (HF).relative risk of mortality up to 1 year [12,13]. Although
Lau et al distinguished between prevalent and new-
onset AF, they showed an increased risk of unadjusted
mortality (HR = 2.94, 95% CI 2.11–4.09) as we did;
however, the investigators also found an increased risk
(HR = 1.42, 95% CI 1.01–1.99) after regression adjust-
ment, contrary to our null finding [11]. It is worth not-
ing that their non-AF population was approximately 12
years younger (mean age = 63 years) than ours. This rela-
tively younger age could have been responsible for the
difference in results between the two studies. The add-
itional findings related to CV-related readmission in our
study would have policy implications, especially for the
Medicare program, when patients survive the initial
events and are transitioned back to the community. The
associated risk of CV-related readmission should be
considered when evaluating the cost-effectiveness of inter-
ventions or therapies in ACS patients with comorbid AF.
There is only one prior study examining the impact of
HF on outcomes beyond hospitalization in patients with
ACS [14]. The GRACE registry reported a higher risk
of 6-month mortality in patients presenting with HF at
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Figure 2 Kaplan–Meier curves for cardiovascular-readmission of acute coronary syndrome patients by comorbid arial fibrillation (AF)
and heart failure (HF).
Table 4 Regression models for mortality and CV-readmission
Mortality CV-related readmission
(N = 795) (N = 705 among patients discharged alive)
HR 95% CI HR 95% CI
Atrial fibrillation 1.15 (0.81–1.64) 1.46 (1.14–1.87)
Heart failure 1.41 (1.05–1.89) 1.61 (1.26–2.06)
Age <75 Reference Reference
Age 75–84 2.68 (1.72–4.19) 0.95 (0.72–1.24)
Age 85+ 4.98 (3.04–8.14) 0.99 (0.75–1.30)
Male 1.18 (0.83–1.68) 0.94 (0.71–1.24)
Female Reference Reference
Race: White Reference Reference
Race: Non-white 0.82 (0.54–1.25) 0.90 (0.65–1.25)
Income: ≥$25,000 0.79 (0.51–1.20) 0.99 (0.78–1.27)
Income: <$25,000 Reference Reference
Education: Some high school or less Reference Reference
Education: High school graduate 0.79 (0.57–1.09) 0.89 (0.68–1.17)
Employment status: Currently employed 0.62 (0.25–1.56) 1.02 (0.58–1.81)
Employment status: Unemployed Reference Reference
Marital status: Married Reference Reference
Marital status: Widowed 1.06 (0.72–1.58) 1.05 (0.75–1.46)
Marital status: Other 1.49 (0.92–2.41) 1.24 (0.88–1.74)
CCI score = 0–1 Reference Reference
CCI score = 2 0.91 (0.59–1.39) 1.14 (0.84–1.54)
CCI score = 3 1.31 (0.81–2.11) 1.20 (0.85–1.70)
CCI score = 4+ 2.19 (1.61–2.99) 1.29 (0.95–1.74)
HR, Hazard Ratio; CI, Confidence Interval; CCI, Charlson Comorbidity Index.
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Table 5 Regression model for total healthcare costs
Total healthcare costs
(N = 795)
Coefficient Relative cost ratio P value
Atrial fibrillation 0.192 1.212 0.008
Heart failure 0.227 1.255 0.001
Age <75 Reference
Age 75–84 0.102 1.107 0.114
Age 85+ −0.023 0.977 0.761
Male 0.012 1.012 0.843
Female Reference
Race: White Reference
Race: Non-white 0.058 1.060 0.471














Marital status: Married Reference
Marital status: Widowed 0.029 1.029 0.664
Marital status: Other 0.148 1.160 0.083
CCI score = 0–1 Reference
CCI score = 2 0.004 1.004 0.958
CCI score = 3 0.079 1.082 0.326
CCI score = 4+ 0.269 1.309 0.004
CCI, Charlson Comorbidity Index.
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representative Medicare population, which followed pa-
tients for up to 2.5 years, also found a 41% higher risk of
mortality associated with preexisting HF. In addition,
we observed a 61% increased risk of CV-related read-
mission. Our findings provide further evidence of HF-
associated long-term burden on elderly ACS patients in
the United States and underscore the importance of
treatment strategies to effectively manage and improve
outcomes for these patients.
Although several earlier studies have examined costs
associated with AF or HF in the Medicare population,
[20-23] the incremental costs of these comorbid condi-
tions have not been examined among ACS patients spe-
cifically. We found that ACS patients with AF or HF
incurred higher costs than their counterparts without
the comorbid condition. Two prior studies reported the
incremental costs of AF in Medicare patients to be
$14,199 and $24,235 [20,21], whereas we found theincremental cost in ACS patients to be $18,555. Differ-
ences in hospitalization rates accounted for half of the
incremental cost of AF. The current literature provides
very little information about incremental costs for Medi-
care HF patients. In this ACS population, we found the
incremental cost of HF to be $18,280; two-thirds of the
incremental costs can be attributed to cost differences in
hospitalization and long-term care facilites. These data
suggest that the economic burden associated with co-
morbid AF and HF in ACS patients may be related to a
higher likelihood of readmission or a greater need for
long-term care placement. Further assessment and inter-
ventions targeting patients with ACS and comorbid AF
and/or HF may help Medicare manage the substantial
economic burden.
The findings of this study should be interpreted in the
context of several limitations. Healthcare costs were
collected through both self-report and Medicare claims
and might be underreported. Self-reported survey data
are subject to recall bias. Diagnoses were determined
from Medicare Part A and Part B claims, and medical
services covered by other insurers or paid out-of-pocket
were not captured. This might have resulted in misclas-
sifying comorbid AF and HF. By the same token, major
outcomes not captured in the dataset might lead to
underestimation of the burden. While regressions were
used to adjust for confounders when assessing the
associated risk of comorbid AF and HF on outcomes,
unobservable confounders might have led to biased
estimates.Conclusion
Using a nationally representative sample of Medicare
beneficiaries, we observed a significant clinical and eco-
nomic burden among patients hospitalized for ACS who
had comorbid AF and HF. Interventions and cost-
effective strategies to improve outcomes and quality of
care for patients with these comorbid conditions should
be considered.Abbreviations
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